
The most common (>20%) adverse reactions are diarrhea, rash, stomatitis, vomiting, decreased appetite, paronychia, nausea, musculoskeletal pain, dry skin, fatigue, cough, pruritus, and decreased weight. The most common (≥2%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes, increased amylase, increased lipase, decreased potassium, decreased red blood cells, increased creatinine, decreased magnesium and increased alanine aminotransferase.
from FDA,2023.09
Mobocertinib is a targeted therapy drug for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Its common side effects include diarrhea, rash, stomatitis, na···【more】
Article source:Lucius LaosRelease date:2026-02-26Recommended:33
Exkivityimproves patient outcomes by inhibiting specific mutant kinases and blocking the proliferation and migration of tumor cells. Exkivityhas been approved by the United States ···【more】
Article source:Lucius LaosRelease date:2024-08-08Recommended:249
Exkivity effectively inhibits the growth and spread of tumor cells by precisely targeting EGFR exon 20 insertion mutations, providing a new treatment option and hope for patients w···【more】
Article source:Lucius LaosRelease date:2024-08-08Recommended:280
Exkivityis an innovative third-representative dermal growth factor receptor (EGFR) tyrosine kinase inhibitor specifically designed for the treatment of patients with non-small cell···【more】
Article source:Lucius LaosRelease date:2024-08-08Recommended:230

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: